BioSpace News Archive

Coagulant Therapeutics Corporation announced data from pre-clinical studies on CT-001, an FVIIa derivative engineered for superior safety and efficacy in a poster presentation titled “CT-001, A Novel Next Generation Factor VIIa, Demonstrates Enhanced Procoagulant Activity in Peripartum Patient Samples” at the Society For Maternal-Fetal Medicine 43rd Annual Pregnancy Meeting in San Francisco, California, February 6-11, 2023.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its first Enzyme-Linked Immunosorbent Assay (ELISA) Kit for the detection and quantitation of residual host cell proteins (HCP) in CHO-based biotherapeutics.

MAIA Biotechnology, Inc. (NYSE American: MAIA) announced today it intends to initiate its second Phase 2 go-to-market trial evaluating THIO, the world’s first telomere-targeting agent, in patients with four cancer indications.

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended December 31, 2022 and provided a business update.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company) today announced the following topline results from its MB-105 European Phase 1 clinical trial assessing the safety and efficacy of Annamycin as a single agent for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML).

Cardiawave SA, a deeptech medical device manufacturer that has developed Valvosoft®, an innovative non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, announces the issuance of 3 new patents in the United States.

NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a Toronto-listed biopharmaceutical company, is developing ExoPTEN, a proprietary platform for producing and loading exosomes with pharmaceutical cargo targeting spinal cord injuries (SCI) intranasally.

Cerevance, a private announced an expansion of its Series B funding round with an additional close of $51 million, bringing the total Series B financing to $116 million.

Acer Therapeutics Inc. (Nasdaq: ACER) today announced full enrollment of its Phase 2a proof of concept trial of ACER-801 (osanetant), a novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist, being investigated as a potential treatment option for moderate to severe Vasomotor Symptoms (VMS) associated with menopause.

SeqLL Inc., a technology company providing life sciences instrumentation and research services, announced that it has entered into a securities purchase agreement with institutional investors to purchase 2,000,000 of its shares of common stock at a purchase price of $0.90 per share of common stock in a registered direct offering.